Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Performance evaluation of the prototype Abbott Alinity hq hematology analyzer.

Van der Beken Y, Van Dalem A, Van Moer G, Segers E, Damiaens S, Hoffmann J, Lakos G, Jochmans K.

Int J Lab Hematol. 2019 Aug;41(4):448-455. doi: 10.1111/ijlh.13020. Epub 2019 May 21.

PMID:
31305028
2.

International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies.

Bentow C, Lakos G, Martis P, Wahl E, Garcia M, Viñas O, Espinosa G, Cervera R, Sjöwall C, Carmona-Fernandes D, Santos MJ, Hanly JG, Mahler M.

Lupus. 2016 Jul;25(8):864-72. doi: 10.1177/0961203316640917.

PMID:
27252263
3.

Detection of anti-dsDNA antibodies by computer-aided automated immunofluorescence analysis.

Lakos G, Gonzalez M, Flaherty D, Bentow C, Ibarra C, Stimson D, Nacario L, Hiemann R, Dervieux T.

J Immunol Methods. 2016 Jun;433:17-22. doi: 10.1016/j.jim.2016.02.019. Epub 2016 Feb 24.

4.

Erratum to: Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis.

Yee A, Webb T, Seaman A, Infantino M, Meacci F, Manfredi M, Benucci M, Lakos G, Favalli E, Schioppo T, Meroni PL, Mahler M.

Immunol Res. 2015 May;62(1):126. doi: 10.1007/s12026-015-8642-4. No abstract available.

PMID:
25796173
5.

Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort.

Heikal NM, Jaskowski TD, Malmberg E, Lakos G, Branch DW, Tebo AE.

Clin Exp Immunol. 2015 May;180(2):218-26. doi: 10.1111/cei.12573.

6.

Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus.

Bentow C, Lakos G, Rosenblum R, Bryant C, Seaman A, Mahler M.

Immunol Res. 2015 Feb;61(1-2):110-6. doi: 10.1007/s12026-014-8601-5.

PMID:
25420962
7.

Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis.

Yee A, Webb T, Seaman A, Infantino M, Meacci F, Manfredi M, Benucci M, Lakos G, Favalli E, Schioppo T, Meroni PL, Mahler M.

Immunol Res. 2015 Feb;61(1-2):24-30. doi: 10.1007/s12026-014-8560-x. Erratum in: Immunol Res. 2015 May;62(1):126. Shioppo, Tommaso [corrected to Schioppo, Tommaso].

PMID:
25391608
8.

Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies.

Webb T, Lakos G, Swart A, Gürtler I, Favalli EG, Schioppo T, Mahler M.

Clin Chim Acta. 2014 Nov 1;437:161-7. doi: 10.1016/j.cca.2014.07.032. Epub 2014 Jul 30.

PMID:
25086283
9.

Anti-nuclear antibody screening using HEp-2 cells.

Buchner C, Bryant C, Eslami A, Lakos G.

J Vis Exp. 2014 Jun 23;(88):e51211. doi: 10.3791/51211.

10.

Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Schulte-Pelkum J, Radice A, Norman GL, Lόpez Hoyos M, Lakos G, Buchner C, Musset L, Miyara M, Stinton L, Mahler M.

J Immunol Res. 2014;2014:185416. doi: 10.1155/2014/185416. Epub 2014 Jun 5. Review.

11.

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni P, Ortel TL, Petri M, Rahman A, Roubey R, Sciascia S, Snyder M, Tebo AE, Tincani A, Willis R.

Autoimmun Rev. 2014 Sep;13(9):917-30. doi: 10.1016/j.autrev.2014.05.001. Epub 2014 May 10. Review.

PMID:
24824074
12.

Analytical and clinical comparison of two fully automated immunoassay systems for the diagnosis of celiac disease.

Lakos G, Norman GL, Mahler M, Martis P, Bentow C, Santora D, Fasano A.

J Immunol Res. 2014;2014:371263. doi: 10.1155/2014/371263. Epub 2014 Mar 13.

13.

Nanotherapeutics in the EU: an overview on current state and future directions.

Hafner A, Lovrić J, Lakoš GP, Pepić I.

Int J Nanomedicine. 2014 Feb 19;9:1005-23. doi: 10.2147/IJN.S55359. eCollection 2014. Review.

14.

Standardization of antiphospholipid antibody testing--historical perspectives and ongoing initiatives.

Willis R, Lakos G, Harris EN.

Semin Thromb Hemost. 2014 Mar;40(2):172-7. doi: 10.1055/s-0033-1364207. Epub 2014 Jan 27. Review.

PMID:
24470286
15.

Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies.

Forastiero R, Papalardo E, Watkins M, Nguyen H, Quirbach C, Jaskal K, Kast M, Teodorescu M, Lakos G, Binder W, Shums Z, Nelson V, Norman G, Puig J, Cox A, Vandam W, Hardy J, Pierangeli S.

Clin Chim Acta. 2014 Jan 20;428:99-105. doi: 10.1016/j.cca.2013.11.009. Epub 2013 Nov 16.

PMID:
24252665
16.

Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens.

Bentow C, Swart A, Wu J, Seaman A, Manfredi M, Infantino M, Benucci M, Lakos G, Mahler M.

Clin Chim Acta. 2013 Sep 23;424:141-7. doi: 10.1016/j.cca.2013.05.011. Epub 2013 May 30.

17.

Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population.

Szekanecz Z, Szabó Z, Zeher M, Soós L, Dankó K, Horváth I, Lakos G.

Immunol Res. 2013 Jul;56(2-3):439-43. doi: 10.1007/s12026-013-8425-8.

PMID:
23592053
18.

Non-invasive monitoring of celiac disease: current practice and recent advances.

Lakos G.

MLO Med Lab Obs. 2012 Dec;44(12):15-6. No abstract available.

PMID:
23330518
19.

Interference in antiphospholipid antibody assays.

Lakos G.

Semin Thromb Hemost. 2012 Jun;38(4):353-9. doi: 10.1055/s-0032-1304714. Epub 2012 Mar 6. Review.

PMID:
22618529
20.

Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies.

Pierangeli SS, Favaloro EJ, Lakos G, Meroni PL, Tincani A, Wong RC, Harris EN.

Clin Chim Acta. 2012 Jan 18;413(1-2):358-60. doi: 10.1016/j.cca.2011.09.048. Epub 2011 Oct 15.

PMID:
22019907
21.

International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies.

Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, Pierangeli SS.

Arthritis Rheum. 2012 Jan;64(1):1-10. doi: 10.1002/art.33349. No abstract available.

22.

Associations of HLA-shared epitope, anti-citrullinated peptide antibodies and lifestyle-related factors in Hungarian patients with rheumatoid arthritis: data from the first Central-Eastern European cohort.

Besenyei T, Gyetvai A, Szabó Z, Fekete A, Kapitány A, Szodoray P, Laki J, Soós L, Sipka S, Szegedi G, Lakos G, Szekanecz Z.

Joint Bone Spine. 2011 Dec;78(6):652-3. doi: 10.1016/j.jbspin.2011.05.018. Epub 2011 Jul 5. No abstract available.

PMID:
21733730
23.

Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat shock protein (anti-hsp65): new biomarkers in ankylosing spondylitis.

Bodnár N, Szekanecz Z, Prohászka Z, Kemény-Beke A, Némethné-Gyurcsik Z, Gulyás K, Lakos G, Sipka S, Szántó S.

Joint Bone Spine. 2012 Jan;79(1):63-6. doi: 10.1016/j.jbspin.2011.03.010. Epub 2011 Jun 16.

PMID:
21683641
24.

IgM, but not IgA rheumatoid factor interferes with anti-cardiolipin and antiβ2 glycoprotein I measurements: a quantitative analysis.

Lakos G, Teodorescu M.

Lupus. 2011 May;20(6):614-9. doi: 10.1177/0961203310393379. Epub 2011 Mar 24.

PMID:
21436214
25.

'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.

Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G, Ortel T, Meroni PL, Otomo K, Pengo V, Tincani A, Wong R, Roubey R.

Lupus. 2011 Feb;20(2):182-90. doi: 10.1177/0961203310395055.

PMID:
21303835
26.

Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome.

Veres K, Szodoray P, Szekanecz Z, Lakos G, Kiss E, Laczik R, Sipka S, Bodolay E, Zeher M, Muszbek L, Szegedi G, Soltész P.

Lupus. 2010 Nov;19(13):1520-6. doi: 10.1177/0961203310374336. Epub 2010 Aug 4.

PMID:
20685773
27.

Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.

Jaskowski TD, Hill HR, Russo KL, Lakos G, Szekanecz Z, Teodorescu M.

J Rheumatol. 2010 Aug 1;37(8):1582-8. doi: 10.3899/jrheum.091236. Epub 2010 Jun 1.

28.

Myth and reality: practical test system for the measurement of anti-DNA antibodies in the diagnosis of systemic lupus erythematosus (SLE).

McCloskey LJ, Christner P, Jacobs-Kosmin D, Jaskowski TD, Hill HR, Lakos G, Teodorescu M.

J Clin Lab Anal. 2010;24(2):77-84. doi: 10.1002/jcla.20358.

PMID:
20333761
29.

Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients.

Váncsa A, Gergely L, Ponyi A, Lakos G, Németh J, Szodoray P, Dankó K.

Joint Bone Spine. 2010 Mar;77(2):125-30. doi: 10.1016/j.jbspin.2009.08.008. Epub 2010 Feb 25.

PMID:
20188618
30.

Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome.

Laczik R, Szodoray P, Veres K, Lakos G, Sipka S, Szegedi G, Soltész P.

Autoimmunity. 2010 Jun;43(4):334-9. doi: 10.3109/08916930903540440.

PMID:
20187701
31.

New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies.

Gyetvai A, Szekanecz Z, Soós L, Szabó Z, Fekete A, Kapitány A, Teodorescu M, Sipka S, Szegedi G, Lakos G.

Rheumatology (Oxford). 2010 Jan;49(1):25-33. doi: 10.1093/rheumatology/kep338. Epub 2009 Nov 17.

PMID:
19920092
32.

Anti-nuscleosome antibody, a reliable indicator for lupus nephritis.

Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P.

Autoimmunity. 2009 Aug;42(5):393-8.

PMID:
19811255
33.

Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus.

Szodoray P, Tarr T, Tumpek J, Kappelmayer J, Lakos G, Poor G, Szegedi G, Kiss E.

Autoimmunity. 2009 Sep;42(6):497-506. doi: 10.1080/08916930902882731.

PMID:
19626489
34.

Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis.

Szodoray P, Szabó Z, Kapitány A, Gyetvai A, Lakos G, Szántó S, Szücs G, Szekanecz Z.

Autoimmun Rev. 2010 Jan;9(3):140-3. doi: 10.1016/j.autrev.2009.04.006. Epub 2009 May 7. Review.

PMID:
19427413
35.

Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study.

Gaál J, Lakos G, Szodoray P, Kiss J, Horváth I, Horkay E, Nagy G, Szegedi A.

Acta Derm Venereol. 2009;89(2):140-4. doi: 10.2340/00015555-0555.

36.

Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Papp M, Altorjay I, Lakos G, Tumpek J, Sipka S, Dinya T, Palatka K, Veres G, Udvardy M, Lakatos PL.

Clin Vaccine Immunol. 2009 Apr;16(4):464-70. doi: 10.1128/CVI.00002-09. Epub 2009 Feb 4.

37.

Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects.

Szekanecz Z, Aleksza M, Antal-Szalmás P, Soltész P, Veres K, Szántó S, Szabó Z, Végvári A, Szamosi S, Lakos G, Sipka S, Szegedi G, Varga J, Szücs G.

Clin Rheumatol. 2009 Mar;28(3):347-50. doi: 10.1007/s10067-008-1062-2. Epub 2008 Dec 6.

PMID:
19067103
38.

Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis.

Szántó S, Aleksza M, Mihály E, Lakos G, Szabó Z, Végvári A, Sipka S, Szekanecz Z.

J Rheumatol. 2008 Dec;35(12):2372-5. doi: 10.3899/jrheum.070839. Epub 2008 Nov 1.

PMID:
19004035
39.

Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma.

Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G, Mori Y, Chang E, Nihijima C, Takehara K, Feghali-Bostwick C, Varga J.

Am J Pathol. 2008 Oct;173(4):1085-99. doi: 10.2353/ajpath.2008.080382. Epub 2008 Sep 4.

40.

Rheumatoid arthritis diagnosis with antimutated citrullinated vimentin ELISA by Orgentec Diagnostika.

Szekanecz Z, Lakos G.

Expert Opin Med Diagn. 2008 Sep;2(9):1083-90. doi: 10.1517/17530059.2.9.1083.

PMID:
23495927
41.

Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.

Lakos G, Soós L, Fekete A, Szabó Z, Zeher M, Horváth IF, Dankó K, Kapitány A, Gyetvai A, Szegedi G, Szekanecz Z.

Clin Exp Rheumatol. 2008 Mar-Apr;26(2):253-60.

PMID:
18565246
42.

Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis.

Kapitány A, Szabó Z, Lakos G, Aleksza M, Végvári A, Soós L, Karányi Z, Sipka S, Szegedi G, Szekanecz Z.

Isr Med Assoc J. 2008 Jan;10(1):32-6.

43.

Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?

Szekanecz Z, Soós L, Szabó Z, Fekete A, Kapitány A, Végvári A, Sipka S, Szücs G, Szántó S, Lakos G.

Clin Rev Allergy Immunol. 2008 Feb;34(1):26-31. doi: 10.1007/s12016-007-8022-5. Review.

PMID:
18270854
44.

Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.

Kerekes G, Szekanecz Z, Dér H, Sándor Z, Lakos G, Muszbek L, Csipö I, Sipka S, Seres I, Paragh G, Kappelmayer J, Szomják E, Veres K, Szegedi G, Shoenfeld Y, Soltész P.

J Rheumatol. 2008 Mar;35(3):398-406. Epub 2008 Jan 15.

PMID:
18203326
45.

Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.

Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, Kiss E.

Clin Rev Allergy Immunol. 2007 Apr;32(2):131-7.

PMID:
17916982
46.

Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation?

Szekanecz E, Sándor Z, Antal-Szalmás P, Soós L, Lakos G, Besenyei T, Szentpétery A, Simkovics E, Szántó J, Kiss E, Koch AE, Szekanecz Z.

Ann N Y Acad Sci. 2007 Jun;1108:359-71.

47.

Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses.

Fekete A, Soos L, Szekanecz Z, Szabo Z, Szodoray P, Barath S, Lakos G.

J Autoimmun. 2007 Sep-Nov;29(2-3):154-63.

PMID:
17826949
48.

Association of HELLP syndrome with primary antiphospholipid syndrome--a case report.

Veres K, Papp K, Lakos G, Szomják E, Szekanecz Z, Szegedi G, Soltész P.

Clin Rheumatol. 2008 Jan;27(1):111-3. Epub 2007 Aug 8.

PMID:
17684701
49.
50.

Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.

Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.

J Rheumatol. 2007 Aug;34(8):1658-63. Epub 2007 Jul 1.

PMID:
17611988

Supplemental Content

Support Center